Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | GDF-8 |
Clinical data | |
Other names | PF-06252616 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6366H9826N1690O2008S46 |
Molar mass | 143639.22 g·mol−1 |
Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.[1][2]
This drug was developed by Pfizer. Pfizer stopped development in 2018 after disappointing results in 2 human trials.[3]